drugset / Trial / NCT07244029

Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery

NCT07244029

Recruiting 100 enrolled Oman Medical Speciality Board
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, single-blind, controlled clinical trial aims to evaluate the efficacy and safety of Aescin-based herbal extract (Reparil®) compared with Ibuprofen in managing postoperative sequelae following surgical removal of impacted mandibular third molars. A total of 100 participants aged 18-40 years will be enrolled at the Dental Center, Medical City Hospital for Military and Security Services (MCMSS), Al Khoud, Oman. Participants will be randomly assigned to receive either Reparil® (Aescin 20 mg, three times daily for five days) or Ibuprofen (400 mg, three times daily for five days) following standardized third molar extraction procedures. Postoperative outcomes including pain (VAS), facial swelling (3D facial scanner), and mouth opening (digital caliper) will be assessed preoperatively, on day 2, and day 7 post-surgery. The study aims to determine whether Aescin offers comparable analgesic and anti-edematous effects to Ibuprofen with fewer adverse events.

Timeline

Start
2026-01-01
Primary completion
2026-07-30
Completion
2026-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Escin Unknown 20 mg Oral
Comparator Ibuprofen Small molecule 400 mg Oral

Indications

No indication recorded.